Search results
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules -...
Benzinga· 4 days agoNBIX today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA< ...
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
Investor's Business Daily· 7 hours agoThe flat base forged next to a prior flat base. Aggressive investors could use Wednesday's high of...
FDA approves INGREZZA SPRINKLE for swallowing difficulties By Investing.com
Investing.com· 4 days agoBiosciences, Inc. (NASDAQ:NBIX) today announced that the U.S. Food and Drug Administration (FDA) has...
Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation
Pharmaceutical Technology via Yahoo Finance· 3 days agoHowever, the exact mechanism of action is unknown, as per Neurocrine. Tardive dyskinesia is a rare...
No. 1 Biotech Stock Pops After Biggest Moneymaker Tops Sales Views
Investor's Business Daily· 3 days agoThe company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia.
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
Investor's Business Daily· 3 days agoBut investors could also use the April 23 high of 145 as an early entry. Neurocrine Stock: Ingrezza...
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
GuruFocus.com via Yahoo Finance· 3 days agoThe company recorded a significant charge of $89 million related to the settlement of convertible notes, impacting financials. While INGREZZA continues to grow, the market ...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoAll of these will be key to helping bolster Neurocrine's sales. The company is well known for ...
Neurocrine Biosciences shares jump 3% on earnings, revenue beat By Investing.com
Investing.com· 3 days agoNeurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) reported a notable increase in its...
Q1 2024 Neurocrine Biosciences Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoToday, May 1 marks the 7-year anniversary since the commercial launch of INGREZZA in 2017. After 7 years, INGREZZA is the #1 prescribed VMAT2 inhibitor ...
